Cargando…
Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment
Resistance against new hepatitis C virus (HCV) antivirals is an area of increasing interest. Resistance-associated substitutions (RASs) have been identified in treatment-naïve individuals, but pressures driving treatment-independent RAS emergence are poorly understood. We analysed the longitudinal e...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282498/ https://www.ncbi.nlm.nih.gov/pubmed/28139734 http://dx.doi.org/10.1038/srep41719 |
_version_ | 1782503333443928064 |
---|---|
author | Eltahla, Auda A. Leung, Preston Pirozyan, Mehdi R. Rodrigo, Chaturaka Grebely, Jason Applegate, Tanya Maher, Lisa Luciani, Fabio Lloyd, Andrew R. Bull, Rowena A. |
author_facet | Eltahla, Auda A. Leung, Preston Pirozyan, Mehdi R. Rodrigo, Chaturaka Grebely, Jason Applegate, Tanya Maher, Lisa Luciani, Fabio Lloyd, Andrew R. Bull, Rowena A. |
author_sort | Eltahla, Auda A. |
collection | PubMed |
description | Resistance against new hepatitis C virus (HCV) antivirals is an area of increasing interest. Resistance-associated substitutions (RASs) have been identified in treatment-naïve individuals, but pressures driving treatment-independent RAS emergence are poorly understood. We analysed the longitudinal evolution of RASs in twelve participants with early acute HCV infections. Full-genome deep sequences were analysed for changes in RAS frequency within NS3, NS5A and NS5B-coding regions over the course of the infection. Emergence of RASs relevant only to the polymerase non-nucleoside inhibitors (NNI) was detected, and these lay within CD8+ T-cell epitopes. Conversely, the loss of NNI RASs over time appeared likely to be driven by viral fitness constraints. These results highlight the importance of monitoring CD8+ T cell epitope-associated RASs in populations with dominant HLA types. |
format | Online Article Text |
id | pubmed-5282498 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-52824982017-02-03 Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment Eltahla, Auda A. Leung, Preston Pirozyan, Mehdi R. Rodrigo, Chaturaka Grebely, Jason Applegate, Tanya Maher, Lisa Luciani, Fabio Lloyd, Andrew R. Bull, Rowena A. Sci Rep Article Resistance against new hepatitis C virus (HCV) antivirals is an area of increasing interest. Resistance-associated substitutions (RASs) have been identified in treatment-naïve individuals, but pressures driving treatment-independent RAS emergence are poorly understood. We analysed the longitudinal evolution of RASs in twelve participants with early acute HCV infections. Full-genome deep sequences were analysed for changes in RAS frequency within NS3, NS5A and NS5B-coding regions over the course of the infection. Emergence of RASs relevant only to the polymerase non-nucleoside inhibitors (NNI) was detected, and these lay within CD8+ T-cell epitopes. Conversely, the loss of NNI RASs over time appeared likely to be driven by viral fitness constraints. These results highlight the importance of monitoring CD8+ T cell epitope-associated RASs in populations with dominant HLA types. Nature Publishing Group 2017-01-31 /pmc/articles/PMC5282498/ /pubmed/28139734 http://dx.doi.org/10.1038/srep41719 Text en Copyright © 2017, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Eltahla, Auda A. Leung, Preston Pirozyan, Mehdi R. Rodrigo, Chaturaka Grebely, Jason Applegate, Tanya Maher, Lisa Luciani, Fabio Lloyd, Andrew R. Bull, Rowena A. Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment |
title | Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment |
title_full | Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment |
title_fullStr | Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment |
title_full_unstemmed | Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment |
title_short | Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment |
title_sort | dynamic evolution of hepatitis c virus resistance-associated substitutions in the absence of antiviral treatment |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282498/ https://www.ncbi.nlm.nih.gov/pubmed/28139734 http://dx.doi.org/10.1038/srep41719 |
work_keys_str_mv | AT eltahlaaudaa dynamicevolutionofhepatitiscvirusresistanceassociatedsubstitutionsintheabsenceofantiviraltreatment AT leungpreston dynamicevolutionofhepatitiscvirusresistanceassociatedsubstitutionsintheabsenceofantiviraltreatment AT pirozyanmehdir dynamicevolutionofhepatitiscvirusresistanceassociatedsubstitutionsintheabsenceofantiviraltreatment AT rodrigochaturaka dynamicevolutionofhepatitiscvirusresistanceassociatedsubstitutionsintheabsenceofantiviraltreatment AT grebelyjason dynamicevolutionofhepatitiscvirusresistanceassociatedsubstitutionsintheabsenceofantiviraltreatment AT applegatetanya dynamicevolutionofhepatitiscvirusresistanceassociatedsubstitutionsintheabsenceofantiviraltreatment AT maherlisa dynamicevolutionofhepatitiscvirusresistanceassociatedsubstitutionsintheabsenceofantiviraltreatment AT lucianifabio dynamicevolutionofhepatitiscvirusresistanceassociatedsubstitutionsintheabsenceofantiviraltreatment AT lloydandrewr dynamicevolutionofhepatitiscvirusresistanceassociatedsubstitutionsintheabsenceofantiviraltreatment AT bullrowenaa dynamicevolutionofhepatitiscvirusresistanceassociatedsubstitutionsintheabsenceofantiviraltreatment |